Search research articles
Contact Us
Filters
Showing results (21-30 of 55) with videos related to
Page
of 6
Sort By:
Current Oncology (Toronto, Ont.)
|
April 3, 2021
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial
Anca Prica, Annette E Hay, Michael Crump, et al.
British Journal of Haematology
|
August 29, 2025
Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia
Tuan Hoang, Matthew C Cheung, David N Juurlink, et al.
Current Oncology (Toronto, Ont.)
|
April 3, 2021
A Canadian Prospective Study of Linkage of Randomized Clinical Trial to Cancer and Mortality Registry Data
Annette E Hay, Nicole Mittmann, Michael Crump, et al.
Blood Advances
|
January 26, 2026
Primary refractory disease in large B cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial
Inna Y Gong, John Kuruvilla, Anca Prica, et al.
Annals of Hematology
|
November 19, 2024
Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists
Anna R Blankstein, Nora Choi, Lee Mozessohn, et al.
Leukemia & Lymphoma
|
June 9, 2016
Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup/>
Tara Baetz, Bingshu E Chen, Stephen Couban, et al.
Leukemia & Lymphoma
|
September 18, 2015
A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191
Annette E Hay, Alli Murugesan, Ashley M DiPasquale, et al.
Leukemia & Lymphoma
|
March 11, 2020
IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia
Sarit Assouline, Lilian Amrein, Raquel Aloyz, et al.
Leukemia & Lymphoma
|
January 18, 2024
Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice
Versha Banerji, Andrew Aw, Nicole Laferriere, et al.
The Journal of Molecular Diagnostics : JMD
|
August 8, 2021
Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay
Christina K Ferrone, Henry Wong, Laura Semenuk, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 55) with videos related to
Sort By:
Page
of 6
Current Oncology (Toronto, Ont.)
|
April 3, 2021
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial
Anca Prica, Annette E Hay, Michael Crump, et al.
British Journal of Haematology
|
August 29, 2025
Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia
Tuan Hoang, Matthew C Cheung, David N Juurlink, et al.
Current Oncology (Toronto, Ont.)
|
April 3, 2021
A Canadian Prospective Study of Linkage of Randomized Clinical Trial to Cancer and Mortality Registry Data
Annette E Hay, Nicole Mittmann, Michael Crump, et al.
Blood Advances
|
January 26, 2026
Primary refractory disease in large B cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial
Inna Y Gong, John Kuruvilla, Anca Prica, et al.
Annals of Hematology
|
November 19, 2024
Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists
Anna R Blankstein, Nora Choi, Lee Mozessohn, et al.
Leukemia & Lymphoma
|
June 9, 2016
Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup/>
Tara Baetz, Bingshu E Chen, Stephen Couban, et al.
Leukemia & Lymphoma
|
September 18, 2015
A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191
Annette E Hay, Alli Murugesan, Ashley M DiPasquale, et al.
Leukemia & Lymphoma
|
March 11, 2020
IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia
Sarit Assouline, Lilian Amrein, Raquel Aloyz, et al.
Leukemia & Lymphoma
|
January 18, 2024
Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice
Versha Banerji, Andrew Aw, Nicole Laferriere, et al.
The Journal of Molecular Diagnostics : JMD
|
August 8, 2021
Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay
Christina K Ferrone, Henry Wong, Laura Semenuk, et al.
Page
of 6